Imunon Inc (IMNN) USD0.01
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Business summary
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Contact details
Important dates
General stock information
- Short code:
- IMNN
- ISIN:
- US15117N6022
- Market cap:
- $16.42 million
- Shares in issue:
- 14.40 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.